ReposiTrak, Inc.

What they do

ReposiTrak operates a business-to-business e-commerce, compliance and traceability, and supply chain management platform. It partners with retailers, wholesalers, distributors and their product suppliers to manage programs such as out-of-stock management and scan-based trading, to reduce supply chain risk by managing compliance documents and data, and to improve product ordering and forecasting. The company markets subscription-based services using Spokes to connect suppliers to retail and wholesale Hubs.

Revenue drivers

• Subscription compliance and traceability platform — Core SaaS revenue from retailers, wholesalers, distributors and suppliers for compliance document management and supply chain risk reduction, marketed under a Hub-and-Spoke connection model.
• Traceability onboarding — Revenue tied to supplier onboarding for FDA traceability; third quarter fiscal 2026 revenue was flat versus the prior-year period because a 16% increase in traceability onboardings in the prior-year quarter did not recur after the FSMA 204 deadline extension.
• Supply chain and ordering/forecasting services — Programs including out-of-stock management, scan-based trading, and product ordering and forecasting intended to accelerate sales and improve supply chain efficiencies.

Recent performance

Third quarter fiscal 2026 total revenue was $5.9 million, essentially flat year over year. Operating expense fell 12% to $3.6 million and operating income rose 24% to $2.3 million. GAAP net income was $2.0 million, up 1%, with EPS of $0.11 basic and $0.10 diluted. Fiscal year-to-date revenue was $17.7 million, up 5%, operating income rose 28% to $6.0 million, and GAAP net income rose 6% to $5.5 million. The company reported $26.4 million in cash, no bank debt, and $5.9 million in cash from operations for the first nine months of fiscal 2026.

Strategy

Management states that the FDA traceability initiative is converging its previously distinct product lines into a single food safety platform, enabling cross-selling from growers to suppliers, wholesalers and retailers. During the quarter the company filed two patent applications covering its Touchless Traceability solution, which it says is in production at a leading grocer and a major Southern wholesaler. It also announced a collaboration with SPAR Group pairing issue identification with in-store field execution. The company returned capital via a $0.02 quarterly dividend declared March 20, 2026, redemption of 35,047 preferred shares for $375,000, and repurchase and cancellation of 55,262 common shares for $550,000.

Risks

• Revenue growth may not continue — The 10-K states there can be no assurance that revenue growth will continue or that operations will remain profitable, and net income was $6,978,127 in fiscal 2025 versus $5,598,290 in fiscal 2024.
• Dependence on founder/CEO — The 10-K states the business depends on the expertise and continued service of founder and CEO Randall K. Fields and that his loss could materially affect operations.
• Subscription marketing strategy execution — The 10-K states that if the strategy of selling subscription-based services and using Spokes to connect to Hubs fails, revenue and operations will be negatively affected.
• Traceability onboarding timing — Third quarter fiscal 2026 revenue was flat because a 16% increase in traceability onboardings in the prior-year quarter did not recur after the FSMA 204 deadline extension.

Outlook

Management points to the FDA traceability initiative as converging its product lines into a single comprehensive food safety platform and describes cross-selling across growers, suppliers, wholesalers and retailers as a strategic advantage. It says Touchless Traceability is already in production at a leading grocer and a major Southern wholesaler and that the two patent applications filed in the quarter create a competitive moat. Management also cites the SPAR Group collaboration as a path from insight to in-store action with potential significance to the industry.